Alkermes

Alkermes — A to Z Product Catalog

Proprietary Marketed Products

• Aristada® (and Aristada Initio®)
  • Generic: Aripiprazole lauroxil (long-acting injectable)
  • Indication: Schizophrenia
  • Dose/Form: Intramuscular injection; dosing intervals vary (monthly, every 6 weeks, or every 2 months) depending on formulation.

• Lybalvi®
  • Generic: Olanzapine + Samidorphan
  • Indication: Schizophrenia and Bipolar I Disorder
  • Dose/Form: Oral tablet, once daily; combination aims to reduce olanzapine-associated weight gain.

• Vivitrol®
  • Generic: Naltrexone (extended-release injectable)
  • Indications: Alcohol dependence and opioid dependence (relapse prevention)
  • Dose/Form: Once-monthly intramuscular injection.

Third-Party Products Utilizing Alkermes Technologies (Licensed or Manufactured)

• Invega Sustenna® / Xeplion®, Invega Trinza® / Trevicta®, Invega Hafyera® / Byannli®
  • Generic: Paliperidone palmitate (long-acting injectable antipsychotics)
  • Indication: Schizophrenia
  • Dose/Form: Long-acting intramuscular injections (monthly, every 3 months).

• Risperdal Consta®
  • Generic: Risperidone in microspheres (long-acting injectable)
  • Indications: Schizophrenia and Bipolar I Disorder
  • Dose/Form: Intramuscular injection, typically every two weeks.

• Vumerity®
  • Generic: Diroximel fumarate (oral immunomodulator)
  • Indication: Multiple sclerosis (relapsing forms)
  • Dose/Form: Oral capsules, twice daily.

Investigational Pipeline

• Alixorexton (ALKS-2680)
  • Descriptor: Oral orexin-2 receptor agonist
  • Indications: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
  • Dose/Form: Once-daily oral; in Phase 2 clinical trials.

• ALKS-4510
  • Descriptor: Investigational neuroscience candidate
  • Indication: Undisclosed neuropsychiatric conditions
  • Dose/Form: Phase 1 clinical-stage.

• ALKS-7290
  • Descriptor: Early-stage neuroscience candidate
  • Indication: Undisclosed neurologic/psychiatric disorders
  • Dose/Form: Preclinical.